GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Debt-to-Revenue

Inoviq (ASX:IIQ) Debt-to-Revenue : 0.60 (As of Jun. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Inoviq Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Inoviq's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.24 Mil. Inoviq's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.16 Mil. Inoviq's annualized Revenue for the quarter that ended in Jun. 2024 was A$0.67 Mil. Inoviq's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.60.


Inoviq Debt-to-Revenue Historical Data

The historical data trend for Inoviq's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inoviq Debt-to-Revenue Chart

Inoviq Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A 2.70 3.61 1.83 0.75

Inoviq Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.39 2.60 1.56 1.44 0.60

Competitive Comparison of Inoviq's Debt-to-Revenue

For the Diagnostics & Research subindustry, Inoviq's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inoviq's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Inoviq's Debt-to-Revenue falls into.



Inoviq Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Inoviq's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.241 + 0.162) / 0.535
=0.75

Inoviq's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.241 + 0.162) / 0.674
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Inoviq Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Inoviq's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Inoviq Business Description

Traded in Other Exchanges
Address
23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq Headlines

No Headlines